Quanterix, ImmunArray partner on neurodegenerative disease

Friday, October 14, 2016

Quanterix, a company digitizing biomarker analysis to accurately measure change for precision health, has announced it is making a strategic investment in ImmunArray, a molecular diagnostics company advancing the development of novel, multi-marker tests for complex diseases with compelling levels of accuracy. As part of the deal, ImmunArray gains access to Quanterix Simoa technology. Both companies are pioneering new approaches to medical diagnoses in complementary areas of neurological disease, focusing on the identification and analysis of molecular biomarkers in the blood.

[Read More]

Quanterix launches Simoa Single Molecule Array technology

Wednesday, July 31, 2013

Quanterix, a company focused on high definition diagnostics, has launched its Single Molecule Array (Simoa) technology, making it commercially available for the first time on a fully automated platform for research use only. Simoa enables life science researchers to explore biomarkers and pathways with greater sensitivity and precision, allowing the development of new diagnostic tests and improved treatment of diseases in oncology, neurology and cardiology.

[Read More]

Madaus joins Quanterix as CEO

Monday, September 19, 2011

Quanterix has named Martin D. Madaus, Ph.D. chief executive officer. Madaus, who also retains his position as chairman, brings more than 20 years of experience in the diagnostics and life science industries, most recently serving as president, chairman and CEO of Millipore, acquired by Merck

[Read More]